109661-96-3

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 107-04-0 1-Bromo-2-chloroethane 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 850152-90-8 1-[2-hydroxy-4-(2-tetrahydro-1H-1-pyrrolylethoxy)phenyl]-1-ethanone 
• 776994-47-9 1-[2-hydroxy-4-(2-piperidinoethoxy)phenyl]-1-ethanone 
• 70744-30-8 1-[2-hydroxy-4-(2-morpholinoethoxy)phenyl]-1-ethanone 
• 850152-84-0 2-(4-methoxyphenyl)-7-[2-(4-phenylpiperazino)ethoxy]-4-chromanone 
• 850153-01-4 1-{2-hydroxy-4-[2-(4-phenylpiperazino)ethoxy]phenyl}-3-(4-methoxyphenyl)-2-propen-1-one 
• 850153-00-3 1-[2-hydroxy-4-(2-piperidinoethoxy)phenyl]-3-(4-methoxyphenyl)-2-propen-1-one 
• 850152-83-9 2-(4-methoxyphenyl)-7-(2-morpholinoethoxy)-4-chromanone 
• 850152-99-7 1-[2-hydroxy-4-(2-morpholinoethoxy)phenyl]-3-(4-methoxyphenyl)-2-propen-1-one 
• 850152-79-3 2-(4-methoxyphenyl)-7-(2-tetrahydro-1H-1-pyrrolylethoxy)-4-chromanone 
• 850152-95-3 1-[2-hydroxy-4-(2-tetrahydro-1H-1-pyrrolylethoxy)phenyl]-3-(4-methoxyphenyl)-2-propen-1-one 

Relevant academic research and scientific papers

Functionalization of the chalcone scaffold for the discovery of novel lead compounds targeting fungal infections

The occurrence of invasive fungal infections represents a substantial threat to human health that is particularly serious in immunocompromised patients. The limited number of antifungal agents, devoid of unwanted toxic effects, has resulted in an increased demand for new drugs. Herein, the chalcone framework was functionalized to develop new antifungal agents able to interfere with cell growth and with the infection process. Thus, a small library of chalcone-based analogues was evaluated in vitro against C. albicans ATCC 10231 and a number of compounds strongly inhibited yeast growth at non-cytotoxic concentrations. Among these, 5 and 7 interfered with the expression of two key virulence factors in C. albicans pathogenesis, namely, hyphae and biofilm formation, while 28 emerged as a potent and broad spectrum antifungal agent, enabling the inhibition of the tested Candida spp. and non-Candida species. Indeed, these compounds combine two modes of action by selectively interfering with growth and, as an added value, weakening microbial virulence. Overall, these compounds could be regarded as promising antifungal candidates worthy of deeper investigation. They also provide a chemical platform through which to perform an optimization process, addressed at improving potency and correcting liabilities.

NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF

The invention relates to novel cyclopenta[b]benzofuran derivatives, to a method for the production thereof and to their utilization for the production of medicaments, especially for the prophylaxis and/or therapy of acute or chronic diseases which are cha

Homopterocarpanes as bridged triarylethylene analogues: Synthesis and antagonistic effects in human MCF-7 breast cancer cells

A series of new compounds structurally derived from 6a,12a-dihydro-6H,7H- [1]-benzopyran-[4,3-b]-benzopyran (homopterocarpane) was efficiently synthesized by reduction of the corresponding pyrilium salts obtained by treatment of selected flavanones and aldehydes with anhydrous HClO4. Cytotoxic effects on the human breast cancer cell line MCF-7 and antiestrogenic activity (only for compounds which resulted more active than tamoxifen (TAM)) on MCF-7 cells stimulated by 17β-estradiol were evaluated. In vivo antiestrogenic activity and the relative binding affinity were also assessed. Some of the new compounds (4c, 4h, 4i and 4l) showed a biological activity in the micromolar range, and were more potent than TAM taken as the reference.